Ginkgo Bioworks Holdings (DNA)
Healthcare
Biotechnology
8.10 $
+0.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Ginkgo Bioworks Holdings (DNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -171 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -45 | -136 | -254 | -252 | -296 | -320 | -171 | |
| 11 | 14 | 29 | 43 | 72 | 63 | 59 | |
| 0.8 | 0.5 | 1,606 | 1,931 | 230 | 112 | 82 | |
| 53 | 3.4 | 1,609 | 1,860 | – | – | – | |
| 11 | -27 | -62 | -37 | 30 | -90 | -44 | |
| 22 | 58 | 57 | 52 | 41 | 63 | 7.7 | |
| -75 | -67 | -73 | -67 | -81 | -62 | -240 | |
| – | – | 1,510 | 1.0 | – | – | – | |
| -0.4 | 91 | -25 | -25 | 0.0 | 0.1 | 19 | |
| 199 | -0.7 | -1.1 | 98 | -1.3 | -0.9 | -0.4 | |
| 410 | 90 | 1,534 | 95 | -3.2 | -1.7 | 18 | |
| 291 | -113 | 1,207 | -223 | -380 | -384 | -393 | |
| -67 | -194 | -310 | -304 | -336 | -382 | -179 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.